TY  - JOUR
A1  - Kunath, Frank
A1  - Krause, Steffen F.
A1  - Wullich, Bernd
A1  - Goebell, Peter J.
A1  - Engehausen, Dirk G.
A1  - Burger, Maximilian
A1  - Meerpohl, Joerg J.
A1  - Keck, Bastian
T1  - Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov
JF  - BMC Urology
N2  - Background: Uro-oncological neoplasms have both a high incidence and mortality rate and are therefore a major public health problem. The aim of this study was to evaluate research activity in uro-oncology over the last decade. 
Methods: We searched MEDLINE and ClinicalTrials.gov systematically for studies on prostatic, urinary bladder, kidney, and testicular neoplasms. The increase in newly published reports per year was analyzed using linear regression. The results are presented with 95% confidence intervals, and a p value <0.05 was considered statistically significant. 
Results: The number of new publications per year increased significantly for prostatic, kidney and urinary bladder neoplasms (all <0.0001). We identified 1,885 randomized controlled trials (RCTs); also for RCTs, the number of newly published reports increased significantly for prostatic (p = 0.001) and kidney cancer (p = 0.005), but not for bladder (p = 0.09) or testicular (p = 0.44) neoplasms. We identified 3,114 registered uro-oncological studies in ClinicalTrials.gov. However, 85% of these studies are focusing on prostatic (45%) and kidney neoplasms (40%), whereas only 11% were registered for bladder cancers. 
Conclusions: While the number of publications on uro-oncologic research rises yearly for prostatic and kidney neoplasms, urothelial carcinomas of the bladder seem to be neglected despite their important clinical role. Clinical research on neoplasms of the urothelial bladder must be explicitly addressed and supported.
KW  - update
KW  - kidney neoplasms
KW  - prostatic neoplasms
KW  - randomized controlled trial
KW  - testicular neoplasms
KW  - surgery
KW  - journals
KW  - EAU guidelines
KW  - radical cystectomy
KW  - urinary bladder neoplasms
KW  - controlled clinical-trials
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122133
VL  - 13
IS  - 56
ER  - 
TY  - JOUR
A1  - Esser, Peter
A1  - Mehnert‐Theuerkauf, Anja
A1  - Friedrich, Michael
A1  - Johansen, Christoffer
A1  - Brähler, Elmar
A1  - Faller, Hermann
A1  - Härter, Martin
A1  - Koch, Uwe
A1  - Schulz, Holger
A1  - Wegscheider, Karl
A1  - Weis, Joachim
A1  - Kuba, Katharina
A1  - Hinz, Andreas
A1  - Hartung, Tim
T1  - Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study
JF  - Psycho‐Oncology
N2  - Objective
In order to optimize psycho‐oncological care, studies that quantify the extent of distress and identify certain risk groups are needed. Among patients with prostate cancer (PCa), findings on depression and anxiety are limited.

Methods
We analyzed data of PCa patients selected from a German multi‐center study. Depression and anxiety were assessed with the PHQ‐9 and the GAD‐7 (cut‐off ≥7). We provided physical symptom burden, calculated absolute and relative risk (AR and RR) of depression and anxiety across patient subsets and between patients and the general population (GP) and tested age as a moderator within the relationship of disease‐specific symptoms with depression and anxiety.

Results
Among 636 participants, the majority reported disease‐specific problems (sexuality: 60%; urination: 52%). AR for depression and anxiety was 23% and 22%, respectively. Significant RR were small, with higher risks of distress in patients who are younger (eg, RR\(_{depression}\) = 1.15; 95%‐CI: 1.06‐1.26), treated with chemotherapy (RR\(_{depression}\)n = 1.46; 95%‐CI: 1.09‐1.96) or having metastases (RR\(_{depression}\) = 1.30; 95%‐CI: 1.02‐1.65). Risk of distress was slightly elevated compared to GP (eg, RR\(_{depression}\) = 1.13; 95%‐CI: 1.07‐1.19). Age moderated the relationship between symptoms and anxiety (B\(_{urination}\) = −0.10, P = .02; B\(_{sexuality}\) = −0.11, P = .01).

Conclusions
Younger patients, those with metastases or treatment with chemotherapy seem to be at elevated risk for distress and should be closely monitored. Many patients suffer from disease‐specific symptom burden, by which younger patients seem to be particularly distressed. Support of coping mechanisms associated with disease‐specific symptom burden seems warranted.
KW  - anxiety
KW  - cancer
KW  - depression
KW  - oncology
KW  - prostatic neoplasms
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218277
VL  - 29
IS  - 10
SP  - 1604
EP  - 1612
ER  -